[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

625.P1.51 625. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 10, 2011: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center)
Synergistic Preclinical Activity of Bortezomib with Suberoylanilide Hydroxamic Acid (SAHA) in Primary Effusion Lymphoma (PEL)

Shruti Bhatt1*, Brittany Ashlock2*, Ngoc Toomey3*, Enrique Mesri, PhD2*, Juan Carlos Ramos, MD3* and Izidore S Lossos, MD3

1Molecular and Cellular Pharmacology, University of Miami, Miami, FL
2Department of Microbiology and Immunology, University of Miami, Miami, FL
3Department of Medicine, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

Antibody-Induced Non-Apoptotic Cell Death in Human Lymphoma and Leukemia Cells Is Mediated Through NADPH Oxidase-Derived Reactive Oxygen Species

Jamie Honeychurch, PhD1*, Waleed Alduaij, MRes2*, Eleanor Cheadle, PhD3*, Mahsa Azizyan, MSc4*, Helene Pelicano, PhD5*, Peng Huang, MD PhD5*, Andrei Ivanov, MD PhD6*, Mark S Cragg, PhD7* and Timothy M Illidge, MD, PhD1

1School of Cancer and Enabling Sciences, University of Manchester, Manchester, United Kingdom
2School of Cancer and Enabling Sciences, University of Manchester, United Kingdom
3CRUK Targeted Therapy Group, School of Cancer & Enabling Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom
4School of Cancer and Enabling Sciences, University of Manchester, Manchester
5Molecular pathology, MD Anderson Cancer Center, Houston, TX
6Beatson Institute, University of Glasgow, Glasgow, United Kingdom
7Tenovus Research Laboratory, University of Southampton, Southampton, United Kingdom

Contrary Functions of NF-κB Signaling in Anti-Cancer Treatment Outcome

Julia Kase1*, Hua Jing2*, Jan R Dörr1*, Maja Milanovic1*, Dido Lenze3*, Michael Grau4*, Gregor Beuster2*, Sujuan Ji1*, Maurice Reimann1*, Peter Lenz4*, Michael Hummel3*, Bernd Dörken1,2, Georg Lenz1*, Claus Scheidereit2*, Soyoung Lee1* and Clemens A Schmitt1,2

1Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic and Molekulares Krebsforschungszentrum, Charité Universitätsmedizin, Berlin, Germany
2Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
3Department of Pathology, Charité Universitätsmedizin, Berlin, Germany
4Department of Physics, Philipps-University, Marburg, Germany

Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma

Silvia Locatelli, PhD1*, Arianna Giacomini, PhD1*, Anna Guidetti, MD1*, Loredana Cleris, PhD2*, Michele Magni, MD3*, Massimo Di Nicola, MD4, Roberta Mortarini, PhD2*, Alessandro M Gianni, MD1*, Andrea Anichini, PhD2* and Carmelo Carlo-Stella, MD5

1Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
2Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano
3Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
4Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
5Onco/Hematology, IRCCS Istituto Clinico Humanitas, Rozzano (Milano), Italy

PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients

Sunil Iyengar, MD*, Andrew J. Clear, BSc*, Andrew Owen*, Lenushka Maharaj, MSc*, Janet Matthews*, Maria Calaminici, MD*, Rebecca Auer, MD*, Essam Ghazaly, MD*, Sameena Iqbal*, John G. Gribben, MD, DSc and Simon Joel, BSc(Hons), PhD*

Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom

Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6

Xiangao Huang, PhD1, Maurizio Di Liberto, Ph.D.1, Jamieson Bretz, Ph.D.1*, David Chiron, PhD1*, Peter Martin, MD2, Morton Coleman, MD2*, Jia Ruan, MD, PhD2, Mitchell R Smith, MD, PhD3, Scott A Ely, M.D.1, Christopher E. Mason, PhD4*, Phoebe Joy Ho, MBBS, DPhil5, John P. Leonard, MD2* and Selina Chen-Kiang, PhD1

1Department of Pathology and Laboratory Medicine, Weill-Cornell Medical College, New York, NY
2Department of Medicine, Division of Hematology-Oncology, Weill-Cornell Medical College, New York, NY
3Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA
4Department of Physiology and Biophysics and Institute for Computation Biomedicine, Weill-Cornell Medical College, New York, NY
5Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia

Cyclin D1 Over-Expressing Mantle Cell Lymphoma Cells Are Hypersensitive to Inhibition of Fatty Acid Synthase (FASN)

Michael A. Dengler1*, Matthias Gutekunst1*, Stephanie Kopacz1*, Heike Horn1*, Ute Hofmann1*, Matthias Schwab1*, German Ott, MD2*, Heiko van der Kuip1* and Walter E. Aulitzky3

1Clinical Pharmacology, Dr. Margarete Fischer Bosch Institute and University of Tuebingen, Stuttgart, Germany
2Robert Bosch Hospital, Stuttgart
3Robert-Bosch-Krankenhaus, Stuttgart, Germany

Manipulating Tumor Associated Macrophages (TAM) in a Mouse Model of B-Cell Non-Hodgkin Lymphoma (NHL)

Simon L. Hallam1*, Juliana Candido2*, Rita Coutinho1*, Eleni Maniati, PhD2*, Richard G Thompson2*, Nico van Rooijen, PhD3*, Thorsten Hagemann, MD PhD2* and John G. Gribben, MD, DSc1

1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
2Centre for Cancer and Inflammation, Barts Cancer Institute, London, United Kingdom
3Vrije University Medical Centre, Department of Molecular Cell Biology, Amsterdam, Netherlands

Improving T Cell Therapy for Relapsed EBV-Negative Hodgkin’s Lymphoma by Targeting Upregulated MAGE-A4

Conrad Russell Y. Cruz, MD1*, Ulrike Gerdemann, MD1*, Ann M. Leen, PhD1, Jessica A. Shafer, MD1*, Stephanie Ku, BS2*, Benjamin Tzou, BS2*, Terzah M. Horton, MD, PhD3, Amanda Copeland, MSN4*, Anas Younes, MD4, Cliona M. Rooney, PhD1*, Helen E. Heslop, MD1 and Catherine M. Bollard, MD1

1Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children's Hospital, Houston, TX
2Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children's Hospital, Houston
3Department of Pediatrics, Baylor College of Medicine, Houston, TX
4Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas

Lukas Kenner1*, Daniela Laimer2*, Helmut Dolznig3*, Paul Vesely4*, Karoline Kollmann5*, Ana-Iris Iris Schiefer6*, Veronika Sexl, MD7,8*, Philipp B Staber, M.D.9*, Gerald Hoefler10*, Josef Penninger11*, Giorgio Inghirami12* and Jaeger Ulrich13

1Inst. Clinical Patholog, Medical University Vienna, Vienna, Austria
2Inst. Clin. Pathol. Vienna, MUW, Vienna, Austria
3Inst. Clin. Pathol. Vienna, Medical University of Vienna, Vienna, Austria
4Institute of Pathology, Medical University Graz, Graz, Austria
5inst. Clin. Pathol. Vienna, medical University of Vienna, vienna, Austria
6Inst. Clin. Pathol. Vienna, medical University of Vienna, vienna, Austria
7Department of Biomedical Science, Medical University of Vienna and Veterinary University Vienna, Vienna, Austria
8Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria
9Institute of Haematology, Medical University Graz, Graz, Austria
10Pathology, Medical University Graz, graz, Austria
11IMBA, Austrian Academy of Science, Vienna, Austria
12Center for Experimental Research and Medical Studies, Turin, Italy
13Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

LFB-R603, a Third-Generation Monoclonal Anti-CD20 Antibody Displays An Additive Antitumor Activity with Antileukemic Chemotherapeutic Agents in Mouse Xenograft Models

Isabel Tourais Esteves, Ph. D.1*, Charles Dumontet, M. D., Ph. D.2, Stéphanie Herveau2*, Lina Reslan, Ph. D.2*, Frédérique Brune, Pharm. D.3*, Laurence Van Overtvelt, Ph. D.1*, Margarita Salcedo, PhD1* and Bénédicte Fournès, Ph. D.1*

1PreClinical Development, LFB Biotechnologies, Les Ulis, France
2Laboratoire de Cytologie Analytique, INSERM UMR 1052 / CNRS 5286, Lyon, France
3Program Management, LFB Biotechnologies, Les Ulis, France

Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels

Magdalena Winiarska, PhD1*, Jacek Bil, MD, PhD2*, Kamil Bojarczuk, BSc2*, Dominika Nowis, MD, PhD1*, Malgorzata Wanczyk, MSc2*, Michal Dwojak2*, Grzegorz Basak, MD, PhD3*, Tomasz Stoklosa, MD, PhD1 and Jakub Golab, MD, PhD1,4*

1Department of Immunology, Medical University of Warsaw, Warsaw, Poland
2Department of Immunology, Medical University of Warsaw
3Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland
4Department 3, Institute of Physical Chemistry, Polish Academy of Sciences, Warsaw, Poland

Pro-Apoptotic Effect of An Anti-CD37 Scfv-Fc Fusion Protein, in Combination with the Anti-CD20 Antibody, Ofatumumab, on Tumor Cells From B-Cell Malignancies

Piotr Smolewski1*, Robak Pawel1*, Barbara Cebula-Obrzut1*, Malgorzata Misiewicz2*, Aleksandra Jeske1*, Agata Majchrzak1*, Scott Stromatt, MD3* and Tadeusz Robak2

1Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland
2Department of Hematology, Medical University of Lodz, Lodz, Poland
3Trubion Pharmaceuticals, Seattle, WA

Pro-Apoptotic Activity of Honokiol Analogues in B-Cell Lymphoid Malignancies

Piotr Smolewski1*, Aleksandra Jeske1*, Agata Majchrzak1*, Barbara Cebula1*, Michael Y Bonner2*, Jack L Arbiser2,3* and Tadeusz Robak4

1Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland
2Department of Dermatology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA
3Atlanta Veterans Administration Hospital, Decatur
4Department of Hematology, Medical University of Lodz, Lodz, Poland

Differential Role of the B-Cell Receptor Pathway in Diffuse Large Cell B Cell Lymphoma: Temsirolimus Has Additive Effects in Combination with the BTK Inhibitor PCI-32765 and PI3K Inhibitor Cal101 but Antagonizes Bortezomib in GCB Subtype

Anna-Katharina Zoellner1*, Stephan Bayerl2*, Marc Weinkauf2*, Georg Hess3*, Wolfgang Hiddemann, MD1,2 and Martin H. Dreyling, PhD1,2

1Department of Internal Medicine III, Ludwig-Maximilian-University Munich, Munich, Germany
2Department of Internal Medicine III, CCG Leukemia, Ludwig-Maximilian-University Munich and Helmholtz Center, Munich, Germany
3Department of Hematology, Oncology, Pneumology, Universitätsmedizin J Gutenberg-University, Mainz, Germany

hsTRAIL/Apo2L Induces Apoptosis in Enteropathy-Associated T-Cell Lymphoma

Marijn Radersma, MD1*, Laura R de Baaij, MD1*, Nathalie J Hijmering2*, Gert Ossenkoppele, MD, PhD3, Chris JLM Meijer, MD, PhD2*, Chris JJ Mulder, MD, PhD1* and Saskia AGM Cillessen, PhD2*

1Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, Netherlands
2Pathology, VU University Medical Center, Amsterdam, Netherlands
3Department of Hematology, VU University Medical Center, Amsterdam, Netherlands

*signifies non-member of ASH